Northfield labs (NASDAQ:NFLD)
Historical Stock Chart
From Jul 2019 to Jul 2024
Northfield Laboratories Inc. (Nasdaq: NFLD) announced
today the appointment of Alan L. Heller, a healthcare industry
veteran, to its Board of Directors.
Mr. Heller has a long and distinguished career in the healthcare
industry. Most recently he was President and Chief Executive Officer
of American Pharmaceutical Partners, a company that develops,
manufactures and markets branded and generic injectable pharmaceutical
products and recently merged with American Bioscience Inc. Prior to
APP, Mr. Heller was an investment advisor on life science transactions
to One Equity Partners, a private equity arm of JP Morgan Chase/Bank
One.
Previously, Mr. Heller served as Senior Vice President and
President Global Renal operations at Baxter Healthcare Corporation,
where he had responsibility for global operations of the Renal and
Transfusion Therapies divisions as well as global manufacturing and
the office of the Chief Scientific Officer.
Prior to joining Baxter, Mr. Heller spent 23 years at G.D. Searle.
He served in a number of positions in general management, sales,
marketing, business development and finance before being named
Co-President and Chief Operating Officer, with responsibility for all
commercial operations worldwide. Subsequent to Searle's acquisition by
Pharmacia, Mr. Heller was Executive Vice President and President,
Searle Operations, overseeing the Searle integration into Pharmacia,
and also serving as a member of the Pharmacia Management Committee.
"We are delighted to welcome Al Heller to our Board. His extensive
experience will be of great value to Northfield," said Steven A.
Gould, M.D., Chairman and Chief Executive Officer.
About Northfield Laboratories
Northfield Laboratories Inc. is a leader in developing an
oxygen-carrying resuscitative fluid, PolyHeme(R), for the treatment of
urgent, large volume blood loss in trauma and resultant surgical
settings. PolyHeme(R) is a solution of chemically modified human
hemoglobin that requires no cross matching and is therefore compatible
with all blood types. It has a shelf life in excess of 12 months.
Enrollment is currently underway in a pivotal Phase III trial of
PolyHeme(R) beginning in the pre-hospital setting. For further
information, visit www.northfieldlabs.com.
This press release contains forward-looking statements concerning,
among other things, Northfield's future business plans and strategies
and clinical and regulatory developments affecting our PolyHeme(R)
blood substitute product. These forward-looking statements are
identified by the use of such terms as "intends," "expects," "plans,"
"estimates," "anticipates," "should," "believes" and similar terms.
These forward-looking statements involve inherent risks and
uncertainties. Our actual results may therefore differ materially from
those predicted by the forward-looking statements because of various
factors and possible events, including our ability to obtain FDA
approval to market PolyHeme commercially, the availability of capital
to finance our clinical trials and ongoing business operations, our
ability to obtain adequate supplies of raw materials and to
manufacture PolyHeme in commercial quantities, our ability to market
PolyHeme successfully, the possibility that competitors will develop
products that will render PolyHeme obsolete or non-competitive, our
ability to protect our intellectual property rights, the possibility
that we may be subject to product liability claims and other legal
actions, our dependency on a limited number of key personnel, the
uncertainty of third party reimbursement for our product and other
risks and uncertainties described from time to time in our periodic
reports filed with the Securities and Exchange Commission, including
our most recently filed quarterly report on Form 10-Q and annual
report on Form 10-K. These forward- looking statements speak only as
of the date of this press release. We do not undertake any obligation
to update or publicly release any revisions to forward-looking
statements to reflect events, circumstances or changes in expectations
after the time such statement is made. All subsequent written and oral
forward-looking statements attributable to Northfield or any person
acting on our behalf are qualified by this cautionary statement.